QS Investors LLC continued to hold its position in shares of Teleflex Incorporated (NYSE:TFX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,504 shares of the medical technology company’s stock at the close of the 2nd quarter. QS Investors LLC’s holdings in Teleflex were worth $312,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. OLD Mutual Customised Solutions Proprietary Ltd. increased its holdings in Teleflex by 200.0% in the 1st quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 900 shares of the medical technology company’s stock worth $174,000 after acquiring an additional 600 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in Teleflex in the 2nd quarter worth approximately $200,000. Calamos Advisors LLC purchased a new stake in Teleflex in the 2nd quarter worth approximately $206,000. Harvey Capital Management Inc. purchased a new stake in Teleflex in the 2nd quarter worth approximately $207,000. Finally, Advisor Partners LLC purchased a new stake in Teleflex in the 2nd quarter worth approximately $212,000. 89.75% of the stock is owned by institutional investors.

In other news, Director Stephen K. M.D. Klasko sold 200 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $211.75, for a total value of $42,350.00. Following the completion of the sale, the director now directly owns 8,080 shares in the company, valued at $1,710,940. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 600 shares of company stock valued at $132,408 over the last 90 days. Company insiders own 2.39% of the company’s stock.

Teleflex Incorporated (NYSE:TFX) opened at 241.99 on Friday. The firm has a 50-day moving average price of $236.75 and a 200 day moving average price of $212.34. The company has a market capitalization of $10.90 billion, a P/E ratio of 46.28 and a beta of 1.07. Teleflex Incorporated has a 1-year low of $136.53 and a 1-year high of $248.68.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $2.04 EPS for the quarter, beating the Zacks’ consensus estimate of $1.91 by $0.13. The business had revenue of $528.60 million during the quarter, compared to analysts’ expectations of $518.98 million. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The business’s revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the business earned $1.89 earnings per share. On average, equities analysts predict that Teleflex Incorporated will post $8.29 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/20/qs-investors-llc-holds-position-in-teleflex-incorporated-tfx.html.

TFX has been the subject of several analyst reports. Morgan Stanley raised shares of Teleflex from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $220.00 to $274.00 in a report on Wednesday, September 6th. Zacks Investment Research raised shares of Teleflex from a “hold” rating to a “buy” rating and set a $261.00 target price for the company in a report on Tuesday, September 12th. Jefferies Group LLC increased their target price on shares of Teleflex from $253.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, September 8th. Barclays PLC reissued a “buy” rating on shares of Teleflex in a report on Monday, June 26th. Finally, Needham & Company LLC increased their target price on shares of Teleflex from $228.00 to $237.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $260.75.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Stock Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related stocks with our FREE daily email newsletter.